AZN

AstraZeneca’s Tagrisso approved in the EU for patients with unresectable NSCLC

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...

December 23, 2024

AstraZeneca plc 33.4% potential upside indicated by JP Morgan

December 11, 2024

AstraZeneca Plc Imfinzi approved in the US for limited-stage SCLC

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...

December 5, 2024

AstraZeneca plc 33.5% potential upside indicated by JP Morgan

November 25, 2024

AstraZeneca plc 38.4% potential upside indicated by JP Morgan

November 15, 2024

AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...

November 12, 2024

AstraZeneca Plc Tezspire meets primary endpoints in WAYPOINT trial

AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients...

November 8, 2024

AstraZeneca’s Wainzua recommended for approval in the UK

AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...

October 21, 2024

AstraZeneca’s Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis

September 18, 2024

AstraZeneca plc -12.4% potential downside indicated by Deutsche

September 6, 2024

AstraZeneca plc 16.3% potential upside indicated by Berenberg Bank

August 13, 2024

AstraZeneca Plc completes acquisition of Amolyt Pharma

AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...

July 15, 2024

Aptamer Group signs agreement with AstraZeneca to explore Optimer delivery vehicles

Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...

July 3, 2024

AstraZeneca plc -11.1% potential downside indicated by Deutsche

July 1, 2024

AstraZeneca plc -12.0% potential downside indicated by Deutsche

June 21, 2024

AstraZeneca’s Imfinzi plus chemotherapy approved in the US for endometrial cancer

AstraZeneca's Imfinzi gains FDA approval for endometrial cancer treatment. Results show significant benefits for patients with dMMR disease...

June 17, 2024

AstraZeneca plc -10.1% potential downside indicated by Jefferies

June 6, 2024

AstraZeneca completes acquisition of Fusion Pharmaceuticals

AstraZeneca completes acquisition of Fusion Pharmaceuticals, enhancing its oncology portfolio with next-gen radioconjugates. Learn more here...

June 5, 2024

AstraZeneca Plc Tagrisso recommended for approval in the EU for NSCLC treatment

AstraZeneca's Tagrisso recommended EU approval for 1st-line treatment of EGFRm NSCLC with positive results from FLAURA2 trial published in NEJM...

June 3, 2024

AstraZeneca Plc aims for $80 billion in revenue by 2030

May 21, 2024

News and Interview Alerts

Company Presentations

Ilika plc: A New Era in Solid-State Battery Innovation – 2024 Investor Presentation

Time Finance PLC Strong Growth and Strategic Progress: A Message from CEO Ed Rimmer

SAE Renewables Future Strategy to 2035 and Investment Case by Graham Reid CEO

One Health Group (AQSE:OHGR) final results presentation

Q&As

Hardman & Co

Volta Finance: Liquid access to outperforming private credit

6 October 2025

Real Estate Credit Investments: What RECI brings to investors

15 September 2025

Chesnara Plc: Showing good operational progress

8 September 2025

Arbuthnot Banking Group 1H’25 results: Growing where it wants to

30 July 2025

Green News

Ferro-Alloy Resources: Vanadium Giant Unveils Feasibility Win and Massive Phase Two Upside (Video)

14 October 2025

Drax Group completes £300m buyback and launches £75m extension tranche

9 October 2025

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

BrokerTalk

Real Estate Credit Investments: What RECI brings to investors

15 September 2025

Ampeak Energy, updated forecasts and a growing BESS pipeline, Zeus Capital

29 August 2025

Ilika hits Stereax production milestone with Cirtec, Cavendish

20 August 2025

Kepler highlights strong gains for JPMorgan European Discovery

13 August 2025

Funds

Diverse Income Trust beats key benchmarks, Gervais shares portfolio insights (LON:DIVI)

14 October 2025

Thor Explorations strong cash flow, profits and management execution impresses Gervais Williams (LON:THX)

13 October 2025

Atalaya Mining “superbly positioned” for rising demand and profits highlights fund manager (LON:ATYM)

13 October 2025

Record plc services becoming “much more valuable” explains upbeat DIVI fund manager (LON:REC)

13 October 2025

Why Real Estate Credit Investments’ Resilience Could Be an Investor’s Hidden Advantage (Video)

13 October 2025

View all Funds, Market Insights and news >>

FTSE 100 News

UK Broker Ratings

Coats Group PLC (COA.L) Investor Outlook: A 47% Potential Upside with Strong Buy Ratings

15 October 2025

CMC Markets (CMCX.L) Stock Analysis: Navigating Potential Upside Amid Market Headwinds

15 October 2025

City of London Investment (CTY.L) Stock Insights: Navigating Through a Data Desert

15 October 2025

Burberry Group PLC (BRBY.L): Investor Outlook Reveals Key Insights and 9.17% Upside

15 October 2025

Cranswick PLC (CWK.L) Investor Outlook: Analyzing a 17.38% Upside Potential

15 October 2025

AZN

AstraZeneca’s Tagrisso approved in the EU for patients with unresectable NSCLC

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...

December 23, 2024

AstraZeneca plc 33.4% potential upside indicated by JP Morgan

December 11, 2024

AstraZeneca Plc Imfinzi approved in the US for limited-stage SCLC

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...

December 5, 2024

AstraZeneca plc 33.5% potential upside indicated by JP Morgan

November 25, 2024

AstraZeneca plc 38.4% potential upside indicated by JP Morgan

November 15, 2024

AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...

November 12, 2024

AstraZeneca Plc Tezspire meets primary endpoints in WAYPOINT trial

AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients...

November 8, 2024

AstraZeneca’s Wainzua recommended for approval in the UK

AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...

October 21, 2024

AstraZeneca’s Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis

September 18, 2024

AstraZeneca plc -12.4% potential downside indicated by Deutsche

September 6, 2024

AstraZeneca plc 16.3% potential upside indicated by Berenberg Bank

August 13, 2024

AstraZeneca Plc completes acquisition of Amolyt Pharma

AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...

July 15, 2024

Aptamer Group signs agreement with AstraZeneca to explore Optimer delivery vehicles

Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...